Abstract
Ten patients each with the nodular and ulcerative forms of cutaneous leishmaniasis were selected by clinical and pathological criteria. Capsule itraconazole was given in a daily dose of 4 mg per kg body weight (max. 200 mg) for 6 weeks. Six patients (60.0%) of the nodular and nine patients (90.0%) of the ulcerative subgroups were cured by strict clinical and parasitological criteria. No major adverse effects were noted. Review after 6 months revealed no recurrences. In another ten patients (control group) not receiving any drug, the lesions showed no significant change except for one patient demonstrating spontaneous remission. Thus, itraconazole has a promising antileishmanial potential in India.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
